Syros Pharmaceuticals マネジメント

マネジメント基準チェック /24

Syros Pharmaceuticalsの CEO はConley Cheeで、 Dec2023年に任命され、の在任期間は 1 年未満です。の年間総報酬は$ 1.04Mで、 46%給与と54%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.49%を直接所有しており、その価値は$ 38.38K 。経営陣と取締役会の平均在任期間はそれぞれ2.6年と11.6年です。

主要情報

Conley Chee

最高経営責任者

US$1.0m

報酬総額

CEO給与比率	46.0%
CEO在任期間	less than a year
CEOの所有権	0.5%
経営陣の平均在職期間	2.6yrs
取締役会の平均在任期間	11.6yrs

経営陣の近況

Recent updates

Syros Pharmaceuticals: Entering A Decisive Era With An Expected 2024 Phase 3 Readout

Jul 02

CEO報酬分析

Syros Pharmaceuticals の収益と比較して、Conley Chee の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Sep 30 2024	n/a	n/a	-US$98m
Jun 30 2024	n/a	n/a	-US$132m
Mar 31 2024	n/a	n/a	-US$144m
Dec 31 2023	US$1m	US$479k	-US$165m

報酬と市場: Conleyの総報酬 ($USD 1.04M ) は、 US市場 ($USD 650.80K ) の同規模の企業の平均を上回っています。

報酬と収益: Conleyの報酬と会社の業績を比較するにはデータが不十分です。

CEO（最高経営責任者

Conley Chee (54 yo)

less than a year

在職期間

US$1,041,697

報酬

Mr. Conley Chee serves as President, Chief Executive Officer & Director at Syros Pharmaceuticals, Inc. since December 02, 2023. He served as Chief Commercial Officer at Syros Pharmaceuticals, Inc. since Se...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Conley Chee	CEO, President & Director	less than a year	US$1.04m	0.49% $ 38.4k
Richard Young	Scientific Founder & Member of Scientific Advisory Board	no data	US$82.15k	0.040% $ 3.1k
Jason Haas	Chief Financial Officer	3.1yrs	US$833.02k	0% $ 0
David Roth	Chief Medical Officer	8.9yrs	US$876.53k	0% $ 0
James Bradner	Founder	no data	データなし	データなし
Nathanael Gray	Scientific Founder & Member of Scientific Advisory Board	no data	データなし	データなし
Gerald Quirk	Chief Legal & Compliance Officer and Chief Business Officer	2.1yrs	US$1.46m	0% $ 0
Lisa Roberts	Vice President of Human Resources	1.8yrs	データなし	データなし
Kristin Stephens	Chief Development Officer	4.4yrs	データなし	0% $ 0

2.6yrs

平均在職期間

56yo

平均年齢

経験豊富な経営陣: SYRSの経営陣は経験豊富であると考えられます ( 2.6年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Conley Chee	CEO, President & Director	less than a year	US$1.04m	0.49% $ 38.4k
Richard Young	Scientific Founder & Member of Scientific Advisory Board	11.6yrs	US$82.15k	0.040% $ 3.1k
Nathanael Gray	Scientific Founder & Member of Scientific Advisory Board	11.6yrs	データなし	データなし
Peter Karl Wirth	Independent Chairman	7.8yrs	US$110.40k	0.060% $ 4.7k
Mark Murcko	Member of Scientific Advisory Board	11.6yrs	データなし	データなし
Nancy Simonian	Director	11.6yrs	US$1.49m	0.66% $ 51.6k
Gerard Evan	Member of Scientific Advisory Board	11.6yrs	データなし	データなし
Scott Biller	Member of Scientific Advisory Board	11.6yrs	データなし	データなし
Bradley Bernstein	Member of Scientific Advisory Board	no data	データなし	データなし
Stefan Knapp	Member of Scientific Advisory Board	11.6yrs	データなし	データなし
Aviv Regev	Member of Scientific Advisory Board	11.6yrs	データなし	データなし
Chris Vakoc	Member of Scientific Advisory Board	11.6yrs	データなし	データなし

11.6yrs

平均在職期間

64yo

平均年齢

経験豊富なボード: SYRSの取締役会は経験豊富で経験豊富です ( 11.6年の平均在任期間)。

Syros Pharmaceuticals マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Chief Financial Officer recently bought US$161k worth of stock

Scientific Founder notifies of intention to sell stock

Syros Pharmaceuticals, Inc., Annual General Meeting, Jun 05, 2024

Director exercised options and sold US$72k worth of stock

Syros Pharmaceuticals, Inc. Announces Chief Executive Officer Changes, Effective December 2, 2023

Insufficient new directors

Recent updates

New major risk - Market cap size

New major risk - Revenue and earnings growth

Syros Pharmaceuticals Announces Topline Data from SELECT-MDS-1 Phase 3 Trial of Tamibarotene in Higher-Risk Myelodysplastic Syndrome with RARA Gene Overexpression

Third quarter 2024 earnings released: US$0.16 loss per share (vs US$1.43 loss in 3Q 2023)

Syros Pharmaceuticals, Inc. to Report Q3, 2024 Results on Oct 31, 2024

Chief Financial Officer recently bought US$161k worth of stock

Price target decreased by 56% to US$8.75

Syros Pharmaceuticals Provides Update on SELECT-AML-1 Phase 2 Clinical Trial

New major risk - Financial position

First half 2024 earnings released: US$0.69 loss per share (vs US$2.15 loss in 1H 2023)

Syros Pharmaceuticals, Inc. to Report Q2, 2024 Results on Jul 31, 2024

Syros Pharmaceuticals: Entering A Decisive Era With An Expected 2024 Phase 3 Readout

Scientific Founder notifies of intention to sell stock

New minor risk - Profitability

First quarter 2024 earnings released: US$0.095 loss per share (vs US$0.85 loss in 1Q 2023)

Syros Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 14, 2024

Syros Pharmaceuticals, Inc., Annual General Meeting, Jun 05, 2024

Syros Pharmaceuticals, Inc. Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpression

Director exercised options and sold US$72k worth of stock

Consensus revenue estimates decrease by 59%, EPS upgraded

No longer forecast to breakeven

Full year 2023 earnings: EPS and revenues miss analyst expectations

Syros Pharmaceuticals, Inc. to Report Fiscal Year 2023 Results on Mar 27, 2024

Syros Pharmaceuticals: Rising Despite Dilution, A Must Look

Forecast to breakeven in 2026

Price target decreased by 12% to US$20.00

Syros Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $44.999989 million.

Syros Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $44.999989 million.

New major risk - Share price stability

Syros Pharmaceuticals Announces Encouraging Initial Data from Randomized Select-AML-1 Phase 2 Clinical Trial Evaluating Tamibarotene in Combination with Venetoclax and Azacitidine

Price target decreased by 16% to US$21.25

New major risk - Revenue and earnings growth

Syros Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 14, 2023

New minor risk - Share price stability

Syros Pharmaceuticals, Inc. Announces Chief Executive Officer Changes, Effective December 2, 2023

Price target decreased by 16% to US$21.25

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Syros Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Price target increased by 10% to US$26.50

Syros Pharmaceuticals Presents Data from Phase 1/1b Clinical Trial of SY-5609 in Advanced Solid Tumors at ASCO Annual Meeting

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Syros Pharmaceuticals, Inc. Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Higher-Risk Myelodysplastic Syndrome

Price target decreased to US$25.40

Syros Pharmaceuticals Announces Publication in Blood Advances Demonstrating the Potential of Tamibarotene in Patients with Rara Gene Overexpression, Supporting Ongoing Clinical Development in Aml and Mds

Syros Presents Safety Lead-In Data from SELECT-AML-1 Trial Evaluating Tamibarotene in Combination with Venetoclax and Azacitidine and Announces Plans to Initiate Randomized Portion of Phase 2 Trial

Consensus revenue estimates fall by 11%

Insufficient new directors

Consensus forecasts updated

Syros Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Syros Pharmaceuticals Regains Compliance with Minimum Bid Requirement

Insider recently bought US$106k worth of stock

Consensus forecasts updated

Syros Pharmaceuticals: A Major Vote Of Confidence From Insiders

Syros Pharmaceuticals, Inc. (NasdaqGS:SYRS) completed the acquisition of Tyme Technologies, Inc. (NasdaqCM:TYME) from a group of shareholders.

Syros gets FDA orphan drug designation for pancreatic cancer treatment SY-5609

Consensus forecasts updated

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Syros Pharmaceuticals Q2 2022 Earnings Preview

Syros Pharmaceuticals, Inc. Receives Positive Opinion on Orphan Drug Designation from the European Medicines Agency for Tamibarotene for the Treatment of MDS

Syros Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Tyme Technologies, Inc. (NasdaqCM:TYME) entered into a definitive merger agreement to acquire Tyme Technologies, Inc. (NasdaqGS:SYRS) from Adage Capital Partners, L.P., Samsara Biocapital, L.P., Jalaa Equities, L.P., Flagship Pioneering Fund VII, CVI Investments, Inc. and others for $67.6 million.

Consensus forecasts updated

Consensus estimates of losses per share improve by 11%

Price target decreased to US$14.00

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Syros Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 16, 2022

Insufficient new directors

マネジメント基準チェック /24